Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.57 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.57 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795083 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL29577310 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| Hydrochloric Acid SCHEMBL27538332 | 0.98 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL781659 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL4688913 | 0.87 | CYP1A2 (0.76) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL5795821 | 0.86 | CYP1A2 (0.74) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL2898307 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL135679 | 0.86 | LMNA (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL9639441 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL6110694 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2C9CYP2C19LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129380-A1 | Method for Estimating Molecular Complexity | CHEMIFY LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| CN-1250192-C | 2,5-diaminopyridine oxidation color display alkali for dyeing keratin fibre | OREAL (FR) | 2006-04-12 | — | — | CN | disclosed |
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2004-04-15 | — | — | US | disclosed |
| CN-1425365-A | 2,5-diaminopyridine oxidation color display alkali for dyeing keratin fibre | OREAL (FR) | 2003-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | CYP1A2 3135/4885CYP2C9 2341/4885CYP2C19 1890/4885 |
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | CYP1A2 2691/4885CYP2C9 3321/4885CYP2C19 2253/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | CYP1A2 3135/4885CYP2C9 2341/4885CYP2C19 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.